Lv61
2260 积分 2023-12-21 加入
Safety and efficacy of the anti-TL1A monoclonal antibody tulisokibart for Crohn's disease: a phase 2a induction trial
9天前
已完结
Anti-TL1A antibody, afimkibart, in moderately-to-severely active ulcerative colitis (TUSCANY-2): a multicentre, double-blind, treat-through, multi-dose, randomised, placebo-controlled, phase 2b trial
9天前
已完结
Key factors governing the reconstitution time of high concentration lyophilized protein formulations
16天前
已完结
GPMAW – a software tool for analyzing proteins and peptides
1个月前
已关闭
Comparative analysis and mechanistic insights into polysorbate 80 stability differences in biopharmaceutical buffer systems
1个月前
已完结
An industry perspective on hyaluronidase co-formulated biopharmaceutics
1个月前
已完结
Impact of Surface Energy and Surface Tension on Vial Fogging within Lyophilized Drug Products
3个月前
已完结
US FDA-approved therapeutic antibodies with high-concentration formulation: summaries and perspectives
3个月前
已完结
Fundamental properties and principal areas of focus in antibody-drug conjugates formulation development
3个月前
已完结
Germinal Centers
4个月前
已完结
皖公网安备34019202002308
